Skip to content

Author

Devananda Devegowda

We have 5 of 76 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Nov 2026

Phytobioactives from Thunbergia fragrans as a Potential Therapeutic Agent Against Oral Squamous Cell Carcinoma: An Integrative Approach.

INTRODUCTION Oral Squamous Cell Carcinoma (OSCC) is one of the most prevalent malignancies in South-Central Asia and is strongly associated with tobacco and alcohol consumption. The limited efficacy and adverse effects of current therapeutic strategies have increased interest in the discovery of plant-derived anticance...

Bhavana Harendra, K. P., Devananda Devegowda et al. · 0 citations
Open access Oct 2026

Global, Regional, and National Burden of Bone Cancers, 1990 to 2023, With Forecasts to 2050: A Systematic Analysis for the Global Burden of Disease Study 2023.

Importance Primary bone cancers include multiple histologic types, with survival differing by age and location. Results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 were analyzed to support policies and initiatives worldwide. Objective To estimate the global burden of bone cancer fr...

C. Monsereenusorn, Catherine Bisignano, Miranda L. May et al. · 0 citations
Aug 2026

Global, Regional, and National Burden of Myocarditis and Its Impairment, 1990-2023.

The findings highlight the need for targeted strategies to improve early diagnosis and reduce the burden of myocarditis, particularly in vulnerable populations and lower-resource settings, while being interpreted in the context of evolving diagnostic and coding practices.

Sooji Lee, Hayeon Lee, Min Seo Kim et al. · 1 citation
Open access Sep 2026

Phenotypic characterization of biofilm and multidrug resistance among clinical isolates of carbapenem-resistant Acinetobacter baumannii in a tertiary care hospital

Background: Acinetobacter baumannii ( A. baumannii ) is a gram-negative, opportunistic bacterium. And it is one of the primary cause of infections associated with healthcare, particularly in intensive care units. Its capacity to build biofilm and acquire multidrug resistance, which increases its virulence and persisten...

Akshaya Paramasivam, Tejashree Anantharaj Urs, Satyasai Badveti et al. · 0 citations
Open access Aug 2026

7-Deshydroxypyrogallin-4-carboxylic acid dietary phytochemical as a putative FTO inhibitor in breast cancer: an integrated computational and cytotoxicity study.

These findings provide a preliminary mechanistic and experimental framework for DCA as a dietary FTO inhibitor in breast cancer, necessitating further validation through orthogonal target engagement assays, m6A quantification, and in vivo tumor models.

Shuaib Pasha, S. Harishkumar, Revanth Handralu Chandraiah et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.